The AACR Annual Meeting 2023 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2023. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is November 17, 2022 (11:59 p.m. ET) and the late-breaking and clinical trials abstract submission deadline is January 12, 2023 (11:59 p.m. ET).
<table>
<thead>
<tr>
<th>CL</th>
<th>Clinical Research (not including clinical trials, see also the Clinical Trials (CT) categories)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL01</td>
<td>Biomarkers</td>
</tr>
<tr>
<td>Biomarkers predictive of therapeutic benefit</td>
<td></td>
</tr>
<tr>
<td>Diagnostic biomarkers</td>
<td></td>
</tr>
<tr>
<td>Early detection biomarkers</td>
<td></td>
</tr>
<tr>
<td>Liquid biopsies: Circulating nucleic acids</td>
<td></td>
</tr>
<tr>
<td>Liquid biopsies: Circulating tumor cells</td>
<td></td>
</tr>
<tr>
<td>Metastasis biomarkers</td>
<td></td>
</tr>
<tr>
<td>Prognostic biomarkers</td>
<td></td>
</tr>
<tr>
<td>Spatial proteomics and transcriptomics</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL02</td>
<td>Biostatistics in Clinical Trials</td>
</tr>
<tr>
<td>Design and analysis of clinical trials</td>
<td></td>
</tr>
<tr>
<td>New study designs: Theory, methodology, and modeling</td>
<td></td>
</tr>
<tr>
<td>Statistical modeling for cancer studies</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL03</td>
<td>Clinical Endocrinology (See also EN01: Molecular, Preclinical, and Clinical Endocrinology)</td>
</tr>
<tr>
<td>Endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Growth factors, receptors, and signal transduction</td>
<td></td>
</tr>
<tr>
<td>Hormone receptors and diagnosis/prognosis</td>
<td></td>
</tr>
<tr>
<td>Hormone signaling and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Hormone synthesis, metabolism, and inhibitors</td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine and other endocrine factors</td>
<td></td>
</tr>
<tr>
<td>Nuclear receptors: Structure and function</td>
<td></td>
</tr>
<tr>
<td>Preclinical studies of endocrine-related cancers</td>
<td></td>
</tr>
<tr>
<td>Receptors and signal transduction</td>
<td></td>
</tr>
<tr>
<td>Steroid hormone receptors</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL04</td>
<td>Clinical Outcomes Research</td>
</tr>
<tr>
<td>Clinical outcomes research</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL05</td>
<td>Clinical Research in the Elderly</td>
</tr>
<tr>
<td>Aging, immunity, and cancer</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL06</td>
<td>Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations</td>
</tr>
<tr>
<td>Biobanking/biospecimen collection</td>
<td></td>
</tr>
<tr>
<td>Clinical trial design</td>
<td></td>
</tr>
<tr>
<td>Community-engaged research/community-participatory research</td>
<td></td>
</tr>
<tr>
<td>Community outreach and patient accrual</td>
<td></td>
</tr>
<tr>
<td>Impact of COVID-19 on patient accrual</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL07</td>
<td>Immuno-oncology (See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)</td>
</tr>
<tr>
<td>Adoptive cell therapy</td>
<td></td>
</tr>
<tr>
<td>Combination immunotherapies</td>
<td></td>
</tr>
<tr>
<td>Immune checkpoints</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by other therapies including chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Immune mechanisms invoked by radiation therapy</td>
<td></td>
</tr>
<tr>
<td>Immune monitoring/clinical correlates</td>
<td></td>
</tr>
<tr>
<td>Immune response to therapies</td>
<td></td>
</tr>
<tr>
<td>Immunomodulatory agents and interventions</td>
<td></td>
</tr>
<tr>
<td>Inflammation, immunity, and cancer</td>
<td></td>
</tr>
<tr>
<td>Modifiers of the tumor microenvironment</td>
<td></td>
</tr>
<tr>
<td>Therapeutic antibodies, including engineered antibodies</td>
<td></td>
</tr>
<tr>
<td>Vaccines (oncolytic and prophylactic)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL08</td>
<td>Pediatric Cancer – Clinical Investigations (See also CT09: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)</td>
</tr>
<tr>
<td>Adolescent and young adult oncology</td>
<td></td>
</tr>
<tr>
<td>Childhood cancer drug development</td>
<td></td>
</tr>
<tr>
<td>Immunotherapeutic approaches to pediatric cancer</td>
<td></td>
</tr>
<tr>
<td>Pediatric cancer predisposition and surveillance</td>
<td></td>
</tr>
<tr>
<td>Survivorship, late effects, and second cancers</td>
<td></td>
</tr>
<tr>
<td>Therapeutic dosing, resistance, and combination therapy application</td>
<td></td>
</tr>
<tr>
<td>Translational pediatric cancer research</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL09</td>
<td>Precision Oncology</td>
</tr>
<tr>
<td>Combination therapy</td>
<td></td>
</tr>
<tr>
<td>Molecular targeted therapy</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL10</td>
<td>Radiation Oncology (See TB07: Radiation Science; ET08: Preclinical Radiotherapeutics)</td>
</tr>
<tr>
<td>Clinical radiotherapeutic studies</td>
<td></td>
</tr>
<tr>
<td>Interventional radiology</td>
<td></td>
</tr>
<tr>
<td>Modification of radiosensitivity</td>
<td></td>
</tr>
<tr>
<td>Radiation-immunotherapy and other radiotherapeutic combinations</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced late effects/second cancers</td>
<td></td>
</tr>
<tr>
<td>Radiation-induced resistance</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL11</td>
<td>Real-World Data and Real-World Evidence</td>
</tr>
<tr>
<td>Analyses using clinic-no-genomic databases</td>
<td></td>
</tr>
<tr>
<td>Clinical informatics and data science</td>
<td></td>
</tr>
<tr>
<td>Retrospective clinical analyses</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL12</td>
<td>Surgical Oncology (including Prophylactic Surgery)</td>
</tr>
<tr>
<td>Surgical oncology</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL13</td>
<td>Survivorship Research and Supportive Care</td>
</tr>
<tr>
<td>Biology of cell and tissue damage</td>
<td></td>
</tr>
<tr>
<td>Cardio-oncology</td>
<td></td>
</tr>
<tr>
<td>Comparative effectiveness research and cost-effective studies</td>
<td></td>
</tr>
<tr>
<td>Late effects of cancer and its treatment, including second cancers</td>
<td></td>
</tr>
<tr>
<td>Psycho-oncology</td>
<td></td>
</tr>
<tr>
<td>Supportive care, palliation, and pain management</td>
<td></td>
</tr>
<tr>
<td>Translational survivorship research</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>CL14</td>
<td>Translational Research – Molecular Biology in Clinical Oncology (See also TB03: In Vivo Imaging)</td>
</tr>
<tr>
<td>Clinical imaging</td>
<td></td>
</tr>
<tr>
<td>Clinical radionuclide theranostics</td>
<td></td>
</tr>
<tr>
<td>Cytogenetics and clinical molecular genetics</td>
<td></td>
</tr>
<tr>
<td>Epigenetic therapy</td>
<td></td>
</tr>
<tr>
<td>Functional and molecular imaging</td>
<td></td>
</tr>
<tr>
<td>Laboratory correlates for targeted agents</td>
<td></td>
</tr>
<tr>
<td>Molecular classification of tumors</td>
<td></td>
</tr>
<tr>
<td>Radiomics</td>
<td></td>
</tr>
<tr>
<td>Tumor staging: Correlation of clinical and molecular markers</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>COVID</td>
<td>COVID-19 and Cancer</td>
</tr>
<tr>
<td>Cancer drug repurposing to treat COVID-19</td>
<td></td>
</tr>
<tr>
<td>Cancer prevention and early detection during the COVID-19 pandemic</td>
<td></td>
</tr>
<tr>
<td>Clinical trials [See also CT02: COVID-19, Cancer, and Clinical Trials (Phase I–Phase IV and Trials in Progress)]</td>
<td></td>
</tr>
<tr>
<td>Continuity of cancer care</td>
<td></td>
</tr>
<tr>
<td>COVID-19 vaccines and immune responses among cancer patients</td>
<td></td>
</tr>
<tr>
<td>Effects of cancer immunotherapies on patients with COVID-19 (with or without cancer)</td>
<td></td>
</tr>
<tr>
<td>Effects of COVID-19 on cancer survivorship</td>
<td></td>
</tr>
<tr>
<td>Epidemiology and registries of COVID-19 and cancer (including biorepositories)</td>
<td></td>
</tr>
<tr>
<td>Health inequities and disparities during the COVID-19 pandemic</td>
<td></td>
</tr>
<tr>
<td>Intersection of the biology of SARS-CoV-2 and cancer</td>
<td></td>
</tr>
<tr>
<td>Risk factors and comorbidities resulting in adverse outcomes for cancer patients with COVID-19</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT CATEGORIES (cont’d)

CT  Clinical Trials

CT01 Clinical Trials in Progress
  Phase I clinical trials in progress
  Phase II clinical trials in progress
  Phase III clinical trials in progress

CT02 COVID-19, Cancer, and Clinical Trials
  (See also COVID01: COVID-19 and Cancer)
  Clinical trials in progress
  Phase I
  Phase II
  Phase III
  Phase IV, observational, and expanded access

CT03 First-in-Human Phase I Clinical Trials
  First-in-human phase I clinical trials

CT04 Phase I Adult Clinical Trials
  (See also ET07: Pharmacology,
   Pharmacogenetics, and Pharmacogenomics)
  Phase I adult clinical trials

CT05 Phase II Adult Clinical Trials
  Phase II adult clinical trials

CT06 Phase III Adult Clinical Trials
  Phase III adult clinical trials

CT07 Phase I, II, or III Clinical Trials in the Elderly
  Phase I, II, or III clinical trials in the elderly

CT08 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
  Phase I, II, or III clinical trials in minorities and medically underserved populations

CT09 Phase I, II, or III Clinical Trials in Pediatric Cancer
  (See also CL08: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)
  Phase I, II, or III clinical trials in pediatric cancer

EN  Endocrinology

EN01 Molecular, Preclinical, and Clinical Endocrinology
  (See also CL03: Clinical Endocrinology)
  Endocrine-related cancers
  Growth factors, receptors, and signal transduction
  Hormone receptors and diagnosis/prognosis
  Hormone signaling and inhibitors
  Hormone synthesis, metabolism, and inhibitors
  Neuroendocrine and other endocrine factors
  Nuclear receptors: Structure and function
  Preclinical studies of endocrine-related cancers
  Receptors and signal transduction
  Steroid hormone receptors
  Other

ET  Experimental and Molecular Therapeutics

ET01 Biological Therapeutic Agents
  (See also CL07: Immuno-oncology; IM01: Preclinical Immunotherapy)
  Antireceptors
  Apoptosis: Therapeutic manipulation
  Growth factor receptors and other surface antigens as targets for therapy
  Oncogenes, tumor suppressor genes, and gene products as targets for therapy
  Protein kinases and phosphatases as targets for therapy
  Role of microenvironment in therapeutic response
  Other

ET02 Drug Discovery
  Antibody technologies
  Biochemical modulators of the therapeutic index
  Combination chemotherapies
  Differentiation therapy
  New targets
  Novel assay technology
  Novel drug delivery systems
  Targeting the tumor microenvironment in drug development
  Other

ET03 Drug Resistance
  Drug resistance in molecular targeted therapies
  Drug transport and metabolism
  Novel mechanisms
  Regulation of gene expression in drug resistance
  Reversal of drug resistance
  Other

ET04 Gene and Vector-Based Therapy
  Antisense molecules
  Gene therapy and radiation studies
  Immune modulators
  Vector systems and targeting strategies
  Other

ET05 Mechanisms of Drug Action
  Cell cycle mechanisms of anticancer drug action
  Cellular responses to anticancer drugs
  Role of the microenvironment in therapeutic response
  Other

ET06 Molecular Targets
  Cell death pathways and treatment DNA damage response
  Identification of molecular targets
  Modulation of DNA repair
  Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
  New nonclinical models for targets
  Other

ET07 Pharmacology, Pharmacogenetics, and Pharmacogenomics
  (See also CT04: Phase I Adult Clinical Trials)
  Cellular pharmacology
  Molecular pharmacology
  Pharmacogenetics and therapeutic response
  Pharmacogenomics
  Pharmacokinetics and pharmacodynamics
  Preclinical toxicology
  Other

ET08 Preclinical Radiotherapeutics
  (See also TB07: Radiation Science; CL10: Radiation Oncology)
  Interactions of new agents with radiation
  Modification of radiosensitivity
  Molecular targets of radiation response
  Normal tissue/cellular stress responses to radiation
  Radioprotectors and radiosensitizers
  Theranostics/radiotheranostics
  Other

ET09 Small Molecule Therapeutic Agents
  DNA-reactive agents
  Epigenetic targets
  HDAC and methyltransferase inhibitors
  Novel antitumor agents
  Novel targets and pathways
  PI3K/AKT inhibitors
  Platinum complexes
  Proteasome inhibitors
  Topoisomerases
  Tubulin agents
  Tyrosine kinase and phosphatase inhibitors
  Other

IM  Immunology

IM01 Preclinical Immunotherapy
  (See also CL07: Immunology; ET01: Biological Therapeutic Agents)
  Adoptive cell therapy
  Combination immunotherapies
  Immune checkpoints
  Immune mechanisms invoked by other therapies including chemotherapy
  Immune mechanisms invoked by radiation therapy
  Immune monitoring/clinical correlates
  Immune response to therapies
  Immunomodulatory agents and interventions
  Inflammation, immunity, and cancer
  Modifiers of the tumor microenvironment
  Therapeutic antibodies, including engineered antibodies
  Vaccines (oncolytic and prophylactic)
  Other

Regular Abstract Submission Deadline: November 17, 2022 (11:59 p.m. ET)
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 12, 2023 (11:59 p.m. ET)
CATEGORIES

ABSTRACT

Other Value and cost issues in cancer care
Tobacco and e-cigarette regulation
Real-world evidence and retrospective
Patient advocacy and engagement
Novel endpoints and biomarkers
Implementation science
International regulatory issues
Cancer survivorship
AACR ANNUAL MEETING 2023

Data science and informatics

SHP01   Science and Health Policy

CL14: Translational Research: Molecular Biology in Clinical Oncology

TB03   In Vivo Imaging

Other

TB06   Pediatric Cancer - Basic Science

Other

TB08   Stem Cell Biology

Adult stem cells
Cancer stem cells
Developmental pathways in cancer
Embryonic stem cells
Stem cell markers
Stem cells and regenerative medicine
in oncology
Other

Other

TB09   Tumor Adhesion

Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

TB10   Tumor Evolution and Heterogeneity

Causes and consequences of tumor heterogeneity
Clonal evolution
Complex adaptive systems
Methods to measure tumor evolution and heterogeneity
Other

TB11   Tumor Microenvironment

Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

Other

TB05   Nonclinical Models of Cancer

3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Other animal and cell models of cancer
Patient-derived xenograft models
Zebrafish models of cancer
Other

Other

TB07   Radiation Science

(See also CL10: Radiation Oncology; ET08: Preclinical Radiotherapeutics)

Other

TB04   Metastasis

Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis-promoting genes
Metastasis suppressor genes
Premetastatic niche
Therapeutic metastasis prevention
Other

Other

TB02   Carcinogenesis

Chemical, environmental, and virus-induced carcinogenesis
Mutagenesis
Other

Other

TB01   Angiogenesis

Angiogenesis and angiogenesis inhibitors
Host-tumor interactions
Molecular mechanisms of angiogenesis
Novel pro- and antiangiogenic factors
Tumor microcirculation and the microenvironment
Other

Other

TB08   Cell Adhesion

Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

Other

TB09   Tumor Adhesion

Cell adhesion and extracellular matrix
Cell-cell adhesion
Drug resistance
Other

Other

TB10   Tumor Evolution and Heterogeneity

Causes and consequences of tumor heterogeneity
Clonal evolution
Complex adaptive systems
Methods to measure tumor evolution and heterogeneity
Other

Other

TB11   Tumor Microenvironment

Chemokines in the microenvironment
Drug targets in the microenvironment
Extracellular matrix and integrins
Gene expression in the microenvironment
Immune cells in the tumor microenvironment
Inflammatory cells as regulators of tumor growth
Microbiome
Organ-specific microenvironments
Proteases and inhibitors in the microenvironment
Tumor dormancy
Tumor/stromal interactions
Tumor-immune system interactions
Other

Other

TB05   Nonclinical Models of Cancer

3-D and tissue recombinant models
Developmental phenotypes of cancer genes
Human-in-mouse models of human cancer
Model organisms in drug discovery
Mouse models of human cancer
Noninvasive imaging in animal models
Organoids
Other animal and cell models of cancer
Patient-derived xenograft models
Zebrafish models of cancer
Other

Other

TB07   Radiation Science

(See also CL10: Radiation Oncology; ET08: Preclinical Radiotherapeutics)

Other

TB04   Metastasis

Actin cytoskeleton
Biomarkers of metastasis
Epithelial/mesenchymal transition (EMT and MET)
Expression profiling of tumor progression and metastasis
Genes that regulate migration and invasion
Imaging of tumor progression and metastasis
Invasion and migration
Metastasis-promoting genes
Metastasis suppressor genes
Premetastatic niche
Therapeutic metastasis prevention
Other

Other

TB02   Carcinogenesis

Chemical, environmental, and virus-induced carcinogenesis
Mutagenesis
Other

Other